Dr. Anil Achyuta is an Investment Director and a Founding Member at TDK Ventures, which is a deep-tech corporate venture fund of TDK. Anil is passionate about the energy and healthcare sectors as he believes these are the most impactful areas to building a sustainable future – a mission directly in line with TDK Ventures’ goal. From his first five investments at TDK, Anil has secured two exits. GenCell IPO’d on Tel Aviv’s Stock Exchange (GNCL:IT) and Origin was acquired by the #1 3-D Printing company in the world, Stratasys for $100M. Anil was voted as one of the Rising Stars in 2021 by Venture Capital Journal and recently, Anil was ranked #2 Rising Star out 20,000 corporate venturing managers globally. Prior to TDK Ventures, Anil held leadership roles at Fortune 500 companies including L'Oréal, Johnson & Johnson, GlaxoSmithKline, and Draper. Anil has a Ph.D. in Chemical Engineering from Northeastern University and has authored over 15 peer-reviewed journal publications and 5 US patents.